Skip to content

Microbot Medical MBOT Net proceeds from sale of equity interest

Net proceeds from sale of equity interest at other companies

CleanSpark logo
CleanSparkCLSK
$0+100%
OS Therapies logo
OS TherapiesOSTX
$3.38M+2,447%
Twenty One Capital
 logo
Twenty One Capital XXI
$311.82M
SVC
Stellar V Capital Corp. Class A Ordinary SharesSVCC
$147M
EMP
Empery Digital Inc. Common stockEMPD
$0-100%
JAC
Jackson Acquisition Company IIJACS
$225.4M

Other financials

Income statement

See full
Revenue$105.0K
Gross profit$2.0K
Operating income-$4.3M-43.0%
Net income-$3.7M-41.1%
EPS (diluted)-$0.05+37.5%

Balance sheet

See full
Cash & equivalents$3.7M+13.7%
Total debt$898.0K+551%
Total equity$74.1M+156%
Total assets$78.1M+153%

Cash flow

See full
Operating cash flow-$5.1M-75.8%
CapEx$108.0K+731%
Free cash flow-$5.2M-78.8%

Valuation

See full
Market cap$128.28M+36.1%
Enterprise value$125.53M+39.0%
P/S674.3×

Profitability

See full
Operating margin25,292.9%
Net margin-3,669.9%
FCF margin-852.8%

Returns & leverage

See full
Return on equity-27.6%-10.2pp
Debt / equity0.0×
Current ratio22.6×+6.4×

Where this comes from

Reported directly by Microbot Medical in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromOtherEquity.

The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Microbot Medical's net proceeds from sale of equity interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Microbot Medical's net proceeds from sale of equity interest?
Microbot Medical (MBOT) reported net proceeds from sale of equity interest of $2.78B in Q4 2025.
What does net proceeds from sale of equity interest mean?
Represents the total cash inflows received from equity-related financing activities outside of standard common stock issuances. This metric captures capital raised through alternative instruments or private placements that bolster the company's liquidity position. It is a key indicator of the company's ability to secure non-dilutive or specialized equity funding to support long-term operations.